Bendamustine and subcutaneous alemtuzumab combination is an effective treatment in relapsed/refractory chronic lymphocytic leukemia patients

Marco Montillo, Alessandra Tedeschi, Gianluca Gaidano, Marta Coscia, Valeria Belsito Petrizzi, Ester Orlandi, Nicola Cascavilla, Paolo Ghia, Marina Motta, Andrea Gallamini, Anna Maria Frustaci, Davide Rossi, Lorenzo De Paoli, Michele Nichelatti, Enrica Morra, Massimo Massaia

Research output: Contribution to journalArticlepeer-review

Original languageEnglish
JournalHaematologica
Volume99
Issue number9
DOIs
Publication statusPublished - Sep 1 2014

Keywords

  • Bendamustine
  • Effective treatment
  • Relapsed/refractory chronic lymphocytic leukemia

ASJC Scopus subject areas

  • Hematology
  • Medicine(all)

Cite this